Interstitial lung disease and pulmonary sarcoidosis

• 1952Isoniazid approved (FDA)
• 1955Prednisone approved (FDA)
• 1973Prednisolone phosphoric acid approved (FDA)
• 1997Rituximab approved (FDA)
• 2011Pirfenidone approved (FDA)
• 2014Nintedanib approved (FDA)
• 2021Avacopan approved (FDA)

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

Interstitial lung disease and pulmonary sarcoidosis are treated today in a limited but real way: treatment is disease-modifying. In fibrotic forms such as idiopathic pulmonary fibrosis, antifibrotic medicines like pirfenidone slow the decline in lung function but do not reverse existing scars. In sarcoidosis, corticosteroids such as prednisone shrink granulomatous inflammation and ease symptoms, though not every patient responds durably. The field's trajectory is forward: 398 trials are active now, with 371 launched over the last five years, including 39 phase-3 studies. The single most important milestone was the 2011 approval of pirfenidone, which proved an antifibrotic drug could change the disease's course. That remains limited, unevenly available, and far from a cure, but it marked the beginning of directed treatment.

Will these medicines do more than just relieve symptoms?

Yes, in a limited sense. Antifibrotic drugs slow lung function decline in pulmonary fibrosis, and corticosteroids can reduce sarcoidosis inflammation. They are disease-modifying, not curative, and may not halt progression in every person.

Are there meaningful clinical trials underway?

Yes. About 371 trials have started in the last five years and 398 are currently active. Among those, 39 have reached phase 3, meaning they are being tested in large late-stage studies. Results will take years but the pace is increasing.

Does a diagnosis mean certain progression or death?

No. The disease spans many subtypes. Rapid, progressive fibrosis is possible, but some forms—especially sarcoidosis—may stay mild or even resolve. Treating early when appropriate can slow decline, though outcomes still vague.

What does 'disease-modifying' mean exactly?

It means the therapy targets the disease mechanism itself, not just symptoms. For fibrosis, this means slowing scarring; for sarcoidosis, controlling inflammation. These changes can improve stability and quality of life, but they don't repair already lost function.

How close are we the ability to stop or reverse damage?

Current approved medicines slow, not stop or reverse. With so many phase-3 trials, earlier interventions and better combinations may emerge over the next several years, but there is no approved agent today that actually undoes fibrosis.